THE FDA DESIGNATED BREAKTHROUGH DEVICE

Detect and monitor brain diseases through typing cadence

Our secret

How do we perform our magic?

Simple: We measure typing inconsistency

Detect and monitor neurological diseases and psychiatric disorders through typing cadence.

NeuraMetrix Typing Cadence (TC) is a patented digital biomarker (US Patents 10,694,947 and 10,694,987 and Australian Patent 2016268858) measuring typing inconsistency.

How do we change the world?

Our Goal is to enable dramatically better care of patients with various neurological diseases or psychiatric disorders by providing physicians with an exceptionally precise and accurate measurement of brain health.​​​ 

Or, as a leading neuroscientist puts it

"Imprecise, inaccessible, and outdated assessments of cognition dominate the mental health world". - Professor Adam Gazzaley, M.D., University of California San Francisco

From the experts

//

"We have been looking for this for 30 years."


- Dr. Robert W. Mahley, M.D. Ph.D.
Senior Investigator, President Emeritus and Founder, Gladstone Institutes, Senior Investigator, Gladstone Institute of Neurological Disease, Professor of Pathology and Medicine, University of California San Francisco, Chairman, NeuraMetrix’ Scientific Advisory Board
​​​​​​​​​​​​​​
//

"We train our Huntington’s patients intensively. I am amazed that the effects are so clearly shown in the inconsistency scores."


- Dr. Christina Lang, M.D. – Department of Neurology, Universität Ulm, Germany
​​​​​​​
//

"This will revolutionize how we treat these poor patients."


- CTO of major hospital system in Scandinavia
​​​​​​​
//

"NeuraMetrix technology has potential to provide first-in-class early detection of affective disorders potentially fast-tracking diagnosis and reducing burden of illness."


- Dr. Martin Schalling, M.D., Professor of Medical Genetics Karolinska Institutet,  Chair Swedish Mental Health Fund
​​​​​​​

Some of our Partners

Boston University School of Medicine LogoBoston University School of Medicine Logo

Sign up for the NeuraMetrix newsletter

Sign up